Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis

Neurology. 2004 Aug 24;63(4):718-20. doi: 10.1212/01.wnl.0000134675.98525.79.


Beta-interferon-1a (betaINF-1a) is well tolerated at low dose (30 microg IM/week) in inclusion body myositis (IBM). The authors investigated the safety and tolerability of high-dose (60 microg IM/week) betaINF-1a in a randomized, placebo-controlled trial in IBM. Twenty-seven of the 30 subjects enrolled completed the study. The adverse event profile was similar for the placebo and betaINF-1a groups. betaINF-1a, at a dose of 60 microg IM/week, is well tolerated in IBM, but no differences in muscle strength or mass were observed between the placebo and betaINF-1a groups at 6 months in this pilot study.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Double-Blind Method
  • Female
  • Humans
  • Interferon beta-1a
  • Interferon-beta / administration & dosage
  • Interferon-beta / adverse effects
  • Interferon-beta / therapeutic use*
  • Male
  • Middle Aged
  • Myositis, Inclusion Body / drug therapy*
  • Pilot Projects
  • Treatment Outcome


  • Interferon-beta
  • Interferon beta-1a